Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey

Background The Risk Evaluation and Mitigation Strategy (REMS) for retigabine/ezogabine (RTG/EZG) required an evaluation of the effectiveness of the communication plan to communicate about the risks with use of RTG/EZG. Objective GlaxoSmithKline conducted a survey to assess understanding of the risk...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs - real world outcomes Jg. 2; H. 4; S. 335 - 344
Hauptverfasser:	Ishihara, Lianna, Beck, Melissa, Travis, Sara, Akintayo, Olusegun, Brickel, Neil
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.12.2015 Springer Nature B.V
Schlagworte:	Communication Convulsions & seizures Demographics Drug stores Epilepsy FDA approval Information dissemination Internal Medicine Medicine Medicine & Public Health Pharmacists Pharmacology/Toxicology Pharmacotherapy Physicians Questionnaires Short Communication Urinary retention United States > US Sales Representative Communication Plan Retigabine Urinary Retention Product Label
ISSN:	2199-1154, 2198-9788
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!